

April. 23, 2020

A Summary Result of an Exploratory Clinical Trial with Muse cell-based product, CL2020, in Patients with Acute Myocardial Infarction

Life Science Institute, Inc.

Life Science Institute, Inc. or LSII (Head office: Chiyoda-ku, Tokyo; President: Seiichi Kiso) is pleased to announce a summary result of an exploratory clinical trial with Muse cell-based product, CL2020, in patients with acute myocardial infarction, or AMI, which has been conducted at GIFU UNIVERSITY HOSPITAL and other clinical sites in Japan since January 2018.

The Summary result demonstrated that CL2020 had favorable safety and tolerability profiles up to 12 weeks after administration as the primary endpoint of this trial. The details of the study have been currently under review of an academic journal. LSII will continue the clinical development of CL2020 for this indication.

LSII is committed to contribute to people's health and well-being around the world by developing the next-generation technologies, including Muse cell-based product and to creation of a society where everyone can live a healthy and peaceful life, "KAITEKI".

About "Muse cells"

Muse cells (multilineage-differentiating stress enduring cells), discovered by Professor Mari Dezawa's group at Tohoku University in 2010, are a novel type of non-tumorigenic pluripotent stem cells that can be differentiated into various kinds of cells in the body. Muse cells are endogenous reparative stem cells distributed in the peripheral blood, bone marrow and connective tissue of organs. Their advantageous characteristics are represented by low safety concerns, unnecessary of gene introduction or differentiation induction prior to administration and of surgical operation for delivering cells because of their specific ability to accumulate to the damaged site after intravenous administration, enabling treating patients only by intravenous drip of Muse cell preparation, one of the simple expedient approaches.